Physician profile
Jill E Tucker
NPI 1629477732
$523.14
in general payments reported to CMS, 2019-2025
12 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2024: $125 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $132.28 | 2021-2025 | Zynyz, Monjuvi |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Tempus Ai, INC | $37.76 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $31.45 | 2025 | Tevimbra |
| Geron Corporation | $28.99 | 2025 | Rytelo |
| Pfizer INC. | $27.50 | 2025 | |
| Glaxosmithkline, LLC. | $25.09 | 2025 | Zejula, Jemperli |
| Genmab U.S., INC. | $24.32 | 2025 | |
| Genentech USA, INC. | $24.14 | 2025 | Polivy |
| Astrazeneca Pharmaceuticals LP | $23.01 | 2025 | Calquence |
| Merck Sharp & Dohme LLC | $23.00 | 2025 | Keytruda Qlex, Keytruda |
| Progenics Pharmaceuticals, INC. | $20.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.